Overview

A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

Status:
Not yet recruiting

Trial end date:
2027-01-20

Target enrollment:

Participant gender:

Summary

This phase I/II trial studies the side effects of tozuleristide in imaging oral cavity squamous cell cancer and high-grade oral cavity dysplasia during surgery. Tozuleristide is an imaging agent that specifically binds to tumor cells. When exposed to near-infrared light, tozuleristide causes tumor cells to fluoresce (light up), so that surgeons may better distinguish tumor cells from healthy cells during surgery.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Washington

Collaborator:

Blaze Bioscience Inc.